Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Drug Shortage Anniversary A Happy Occasion For The Agency

This article was originally published in The Pink Sheet Daily

Executive Summary

In the six months since an executive order encouraged firms to provide early notification of potential shortages, FDA has prevented 128 of them, FDA Commissioner Hamburg reports. She attributes the success to manufacturers’ early notification of potential disruptions in drug supply.

You may also be interested in...



User Fee Bill Or Drug Pricing Bill? House Members Makes Both Cases

House passes bill reauthorizing FDA user fee programs via voice vote and makes many other policy changes, but in the process touts the bill's potential to push drug prices lower.

GPhA’s Drug Shortage Initiative Clears FTC Hurdle; Still Working With FDA

Five manufacturers have agreed to give IMS Health production and supply information about drugs in short supply; GPhA and IMS are working with FDA to finalize the details of the accelerated recovery initiative.

GPhA’s Drug Shortage Initiative Clears FTC Hurdle; Still Working With FDA

Five manufacturers have agreed to give IMS Health production and supply information about drugs in short supply; GPhA and IMS are working with FDA to finalize the details of the accelerated recovery initiative.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel